Top

Published in:

01-09-2019 | Original Article

Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments

Authors: Nicolas Turmel, Pierre Lévy, Claire Hentzen, Camille Chesnel, Audrey Charlanes, Samer Sheikh-Ismael, Gérard Amarenco, Philippe Manceau

Published in: World Journal of Urology | Issue 9/2019

Abstract

Objectives

To develop a new tool to assess constraints due to urinary treatments in neurological patients.

Materials and methods

A prospective, monocentric study has been conducted from January to May 2017. Out-patients (multiple sclerosis, spinal cord injury, Parkinson disease) were included in a referral center if they had LUTS treatment for at least 3 months. To validate psychometric properties, we conducted a literature review, qualitative interviews, and discussion with a panel of six experts. Comprehension, acceptation, and pertinence were tested by a pilot study. A validation study, designed to calculate content validity, internal consistency reliability, and test–retest reliability [intraclass correlation coefficient (ICC)] has been conducted. The primary outcome was good psychometric properties defined with Cronbach’s α > 0.7 and ICC > 0.7.

Results

Comprehension, acceptation, and pertinence were excellent. Validation study showed a perfect content validity (r2 = 1) and excellent internal consistency reliability (Cronbach’ α = 0.90). Total score was between 0 (best score) to 66 (maximal constraints). Test–retest reliability calculated using ICC was 0.81. Time to fill questionnaire was 4 min 20 s. The final version was composed by 22 items.

Conclusion

LUTS TCA is the first validated tool to assess constraints of urinary treatment and has excellent psychometric properties.

Available only for authorised users

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 61(1):37–49CrossRefPubMed

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108(7):1132–1138 (Epub 13 Jan 2011) CrossRef

Reynolds WS, Fowke J, Dmochowski R (2016) The burden of overactive bladder on US Public Health. Curr Bladder Dysfunct Rep 11(1):8–13 (Epub 23 Jan 2016) CrossRefPubMedPubMedCentral

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M et al (2017) Qualitative exploration of the patient experience of underactive bladder. Eur Urol. https://doi.org/10.1016/j.eururo.2017.03.045 CrossRefPubMed

Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR (2012) Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol 61(1):88–95 (Epub 26 July 2011) CrossRefPubMed

Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350(8):786–799CrossRefPubMed

Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R et al (2016) Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol 69(2):324–33. https://doi.org/10.1016/j.eururo.2015.07.071 (Epub 22 Aug 2015) CrossRefPubMed

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E et al (2014) Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 65(4):755–65. https://doi.org/10.1016/j.eururo.2013.11.010 (Epub 1 Nov 2013, review) CrossRefPubMed

Noblett K, Siegel S, Mangel J, Griebling TL, Sutherland SE, Bird ET et al (2016) Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 35(2):246–51 (Epub 24 Dec 2014) CrossRefPubMed

10.

Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF (2017) Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 69:77–96 (Epub 14 Nov 2016) CrossRefPubMed

11.

Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68(3):418–25. https://doi.org/10.1016/j.eururo.2014.11.006 (Epub 20 Nov 2014) CrossRefPubMed

12.

Fermanian J (2005) Validation of assessment scales in physical medicine and rehabilitation: how are psychometric properties determined? Ann Readapt Med Phys 48(6):281–287 (Epub 25 Apr 2005) CrossRefPubMed

13.

Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, al. (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 26(2):12CrossRef

14.

Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL (2008) Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). Value Health 11(5):913–926 (Epub 20 May 2008) CrossRefPubMed

15.

Shikiar R, Rentz AM (2004) Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 7(2):204–215CrossRefPubMed

16.

Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM (2012) Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 62(6):1040–1060 (Epub 7 Sep 2012) CrossRefPubMed

17.

Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, Haab F et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53(2):275–287 (Epub 16 Oct 2007)

Title: Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments
Authors: Nicolas Turmel
Pierre Lévy
Claire Hentzen
Camille Chesnel
Audrey Charlanes
Samer Sheikh-Ismael
Gérard Amarenco
Philippe Manceau
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 9/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2580-4

At a glance: The STEP trials

Springer Medicine

Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments

Abstract

Objectives

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2019

A newly developed porcine training model for transurethral piecemeal and en bloc resection of bladder tumour

Predicting posterior urethral obstruction in boys with lower urinary tract symptoms using deep artificial neural network

The prognostic role of preoperative circulating neutrophil–lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis

Predictors of thrombosis in testicular cancer during platinum-based chemotherapy

The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer

Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?